Recursion pricing
No price is published because no software license is sold. The Recursion OS runs internally, and the commercial relationship is a discovery partnership with upfront payments, research funding, milestones and royalties negotiated per deal.
How Recursion pricing works
- Pricing model
- Discovery partnership with upfront payments, research funding, milestones and royalties. No software license is sold.
- Implementation
- Not applicable. There is no customer deployment.
As a listed company Recursion discloses aggregate partnership economics in its financial reporting, such as total potential milestones across the portfolio and payments received to date, but those figures describe what particular partners negotiated, not a price a new partner can apply. A standard collaboration structure, how rights to platform designed molecules are split, and whether Recursion's own pipeline competes in a partner's indications are not published.
Recursion pricing against its alternatives
Published prices for Recursion and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.
- RRecursionNot applicable
- XXaira TherapeuticsNot applicable
- IInsilico MedicineNo published price
- SSchrödingerNo published price
- EEikon TherapeuticsNot applicable
- PPostEraNo published price
- DDeep GenomicsNo published price
- NNumerion LabsNo published price
- CChemifyNo published price
Recursion pricing, answered
How much does Recursion cost?
Recursion does not publish a price. The Recursion OS runs internally, and the commercial relationship is a discovery partnership with upfront payments, research funding, milestones and royalties negotiated per deal.